Mission BioCapital Platinum Programme
Share this opportunity
Apply before 15 May 2026 for next Mission BioCapital Platinum Programme, designed to help early-stage biotech projects
Mission BioCapital (MBC), in partnership with sponsors AbbVie, Ono Venture Investment (OVI), Toronto Innovation Acceleration Partners (TIAP), Connecticut Innovations, Alloy Therapeutics, HitGen, CCRM, Goodwin, Norton Rose Fulbright, and van den Boom & Associates announced today that applications are open internationally for the 2026 Platinum Programme. MBC’s Platinum Programme aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expert mentorship, and discovery services to accelerate their launch and initial development. Early-stage biotechnology innovators from around the globe are invited to apply.
“Since 2022, Mission BioCapital’s Platinum Program has helped launch 24 exceptional early-stage founders, deploying a total of $11.5 million in pre-seed funding and hands-on support to turn breakthrough ideas into medical breakthroughs,” said Jennifer Griffin, Ph.D., Partner, Mission BioCapital. “We’re thrilled to celebrate our alumni’s ongoing achievements and excited to extend Platinum Program access to the next wave of biotech visionaries from around the world.”
The 2026 Platinum Program will award each of up to eight winning start-ups:
- A guaranteed lab bench in one of MBC’s 31 affiliated incubators located in 22 cities in the U.S., Canada, Europe, and Japan
- Up to $500,000 of pre-seed capital from MBC, AbbVie, OVI, TIAP, and Connecticut Innovations
- Drug discovery services from Alloy Therapeutics and HitGen to enable companies with a derisked path to lead candidate
- Consulting support from any affiliates within the CCRM group of companies
- General counsel, intellectual property, and finance and accounting services from Goodwin, Norton Rose Fulbright, and van den Boom & Associates
- Strategic scientific and business development mentorship from experts at MBC, AbbVie, OVI, Alloy Therapeutics, HitGen, CCRM, and other companies across MBC’s corporate network
⏰ Deadline: 15 May 2026 | ➡️ Application